dc.contributor.author | Sjögreen Gleisner, K | |
dc.contributor.author | Spezi, E | |
dc.contributor.author | Solny, P | |
dc.contributor.author | Gabina, PM | |
dc.contributor.author | Cicone, F | |
dc.contributor.author | Stokke, C | |
dc.contributor.author | Chiesa, C | |
dc.contributor.author | Paphiti, M | |
dc.contributor.author | Brans, B | |
dc.contributor.author | Sandström, M | |
dc.contributor.author | Tipping, J | |
dc.contributor.author | Konijnenberg, M | |
dc.contributor.author | Flux, G | |
dc.date.accessioned | 2018-01-02T12:29:56Z | |
dc.date.issued | 2017-12-04 | |
dc.identifier.citation | EJNMMI physics, 2017, 4 (1), pp. 28 - ? | |
dc.identifier.issn | 2197-7364 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/988 | |
dc.identifier.eissn | 2197-7364 | |
dc.identifier.doi | 10.1186/s40658-017-0193-4 | |
dc.description.abstract | BACKGROUND:Currently, the implementation of dosimetry in molecular radiotherapy (MRT) is not well investigated, and in view of the Council Directive (2013/59/Euratom), there is a need to understand the current availability of dosimetry-based MRT in clinical practice and research studies. The aim of this study was to assess the current practice of MRT and dosimetry across European countries. METHODS:An electronic questionnaire was distributed to European countries. This addressed 18 explicitly considered therapies, and for each therapy, a similar set of questions were included. Questions covered the number of patients and treatments during 2015, involvement of medical specialties and medical physicists, implementation of absorbed dose planning, post-therapy imaging and dosimetry, and the basis of therapy prescription. RESULTS:Responses were obtained from 26 countries and 208 hospitals, administering in total 42,853 treatments. The most common therapies were 131I-NaI for benign thyroid diseases and thyroid ablation of adults. The involvement of a medical physicist (mean over all 18 therapies) was reported to be either minority or never by 32% of the responders. The percentage of responders that reported that dosimetry was included on an always/majority basis differed between the therapies and showed a median value of 36%. The highest percentages were obtained for 177Lu-PSMA therapy (100%), 90Y microspheres of glass (84%) and resin (82%), 131I-mIBG for neuroblastoma (59%), and 131I-NaI for benign thyroid diseases (54%). The majority of therapies were prescribed based on fixed-activity protocols. The highest number of absorbed-dose based prescriptions were reported for 90Y microsphere treatments in the liver (64% and 96% of responses for resin and glass, respectively), 131I-NaI treatment of benign thyroid diseases (38% of responses), and for 131I-mIBG treatment of neuroblastoma (18% of responses). CONCLUSIONS:There is a wide variation in MRT practice across Europe and for different therapies, including the extent of medical-physicist involvement and the implementation of dosimetry-guided treatments. | |
dc.format | Electronic | |
dc.format.extent | 28 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-11-06 | |
rioxxterms.versionofrecord | 10.1186/s40658-017-0193-4 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2017-12-04 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | EJNMMI physics | |
pubs.issue | 1 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 4 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Radioisotope Physics | en_US |
dc.contributor.icrauthor | Flux, Glenn | en |
dc.contributor.icrauthor | Marsden, | en |